North America pain management market 2025: Industry Developments, Future Growth, Share & Industry Insights | Bayer AG, Kenvue, Teva Pharmaceuticals Ltd, Viatris Inc, Pfizer Inc.

North America pain management market reached US$ 25.85 billion in 2024 and is expected to reach US$ 46.87 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025-2033.

According to DataM Intelligence Comprehensive Report has released its latest report on the "North America Pain Management Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/north-america-pain-management-market?sg

Industry Latest News 2025:

✅ 30 Jan 2025 - The suzetrigine (brand name JOURNAVX), an oral non‐opioid analgesic developed by Vertex Pharmaceuticals, was approved by the U.S. Food & Drug Administration (FDA) for treatment of moderate‐to‐severe acute pain in adults.

✅ 10 Apr 2025 - A review article noted increasing momentum in non‐opioid pain treatments in the U.S., citing the above approval and other pipeline advances.

✅ 3 Apr 2025 - Globus Medical completed its acquisition of Nevro Corp., a company specializing in spinal‐cord stimulation devices for chronic pain management.

✅ 2 May 2025 - electroCore, Inc. completed the acquisition of NeuroMetrix, Inc. (including its Quell® fibromyalgia stimulus solution), expanding its non‐invasive bioelectronic pain management portfolio.

✅ 2 Nov 2025 - North American Spine & Pain announced a new integrated clinic‐based approach to back and spinal pain management, combining advanced injection therapies with diagnostics in its U.S. network.

✅ 2 Oct 2025 - Tonix Pharmaceuticals reported that its non‐opioid fibromyalgia drug TonmyaTM (cyclobenzaprine HCl sublingual tablets) is scheduled for launch in November 2025 in the U.S.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/north-america-pain-management-market?sg

Market Growth Drivers:

✅ Rising Prevalence of Chronic Pain Conditions

Chronic pain, including back pain, arthritis, neuropathic pain, and cancer-related pain, affects a significant portion of the population in North America. Increasing incidence of musculoskeletal disorders and lifestyle-related health issues is driving the demand for effective pain management solutions.

✅ Aging Population

North America has a growing elderly population, particularly in the United States and Canada. Aging individuals are more prone to chronic pain conditions, which increases the consumption of pain management therapies, including analgesics, nerve stimulation devices, and minimally invasive procedures.

✅ Technological Advancements in Pain Management

Innovations such as wearable pain monitoring devices, targeted drug delivery systems, and minimally invasive surgical interventions are improving patient outcomes. Adoption of advanced devices like spinal cord stimulators and neuromodulation technologies is enhancing treatment efficiency and driving market growth.

✅ Increased Awareness and Patient Education

Patients are increasingly aware of treatment options for pain management due to health awareness campaigns and digital health platforms. Enhanced education on chronic pain conditions encourages timely diagnosis and treatment, thereby boosting market demand.

✅ Growth in Outpatient and Home Healthcare Services

Rising preference for outpatient care and home-based pain management therapies is expanding access to treatment. Remote monitoring devices and telehealth platforms facilitate continuous patient care, further stimulating market growth.

✅ Rising Focus on Non-Opioid Therapies

With growing concerns regarding opioid addiction and side effects, there is a shift toward non-opioid pain management options, including NSAIDs, biologics, and alternative therapies. Regulatory support for safer therapies is encouraging innovation and adoption.

Segments Covered in the Beverage Premix Market:

By Drug Type - Non-Steroidal Anti-Inflammatory Drugs, Opioids, Corticosteroids, Muscle Relaxants, Anticonvulsant Drugs, Others

By Indication - Arthritis Pain, Back Pain, Surgery Pain, Headaches & Migraine, Injury Pain, Cancer Pain, Fibromyalgia, Muscle Spasms, Menstrual Pain, Neuropathic Pain, Others

By Mode of Prescription - Prescription Based, Over-the-Counter

By Distribution Channel - Retail Pharmacies, Hospital Pharmacies, Clinics, Online Pharmacies, Others

Regional Analysis for Beverage Premix Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=north-america-pain-management-market?sg

Major Key Players:
Bayer AG
Kenvue
Teva Pharmaceuticals Industries Ltd.
Viatris Inc.
Pfizer Inc.
Purdue Pharmaceuticals L.P.
Abbott,
Collegium Pharmaceutical, Inc.
Sun Pharmaceutical Industries Ltd.
Virpax Pharmaceuticals.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.